Get started
Author

Lemlem T. Degefie

Observed names: L. Degefie, Lemlem Degefie
Institution: Zymeworks (Canada)
ORCID: 0000-0001-6927-8973
Observed ORCID: 0000-0001-6927-8973
OpenAlex ID: A5089356754
Meis1 establishes the pre-hemogenic endothelial state prior to Runx1 expression
2023 · Patrick Coulombe, Grace Cole, et al. · Nature Communications · 22
PDF
Abstract 1533: ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Andrea Hernandez Rojas, Jodi Wong, et al. · Cancer Research · 3
Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
2024 · Stuart D. Barnscher, Dunja Urosev, et al. · Cancer Research · 2
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al. · Clinical Cancer Research · 1
6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
2024 · A. Hernandez, D. Urosev, et al. · European Journal of Cancer · 1
Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications
2024 · Sam Lawn, Andrea Hernandez Rojas, et al. · Cancer Research · 1
Meis1 Establishes the Pre-Hemogenic Endothelial State Prior to Runx1 Expression
2022 · Grace Cole, Patrick Coulombe, et al. · Blood · 1
Supplementary Figure S1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Data from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S10 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S7 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S12 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S9 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S6 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S13 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S4 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S8 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S11 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S5 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Abstract 1707: ZW191 - a differentiated FRα-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs
2026 · Sam Lawn, Andrea Hernández Rojas, et al. · Cancer Research
Works count: 27
Citation count: 31
H-index: 2
I10-index: 1
Year
Topic
Type